Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Average Recommendation of "Buy" from Brokerages

Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report) have received an average rating of "Buy" from the eight analysts that are currently covering the company, Marketbeat.com reports. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $40.50.

Separately, HC Wainwright reiterated a "buy" rating and issued a $38.00 price target on shares of Pliant Therapeutics in a research note on Friday, November 8th.

Institutional Investors Weigh In On Pliant Therapeutics

A number of hedge funds have recently added to or reduced their stakes in PLRX. Great Point Partners LLC raised its stake in shares of Pliant Therapeutics by 42.4% during the second quarter. Great Point Partners LLC now owns 2,636,864 shares of the company's stock valued at $28,346,000 after purchasing an additional 785,000 shares in the last quarter. State Street Corp raised its position in shares of Pliant Therapeutics by 1.9% during the 3rd quarter. State Street Corp now owns 1,402,730 shares of the company's stock worth $15,725,000 after buying an additional 26,610 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Pliant Therapeutics by 2.4% in the 3rd quarter. Geode Capital Management LLC now owns 1,318,308 shares of the company's stock worth $14,781,000 after acquiring an additional 31,221 shares during the period. Franklin Resources Inc. lifted its stake in shares of Pliant Therapeutics by 1.5% in the 3rd quarter. Franklin Resources Inc. now owns 1,039,904 shares of the company's stock worth $11,657,000 after acquiring an additional 14,913 shares during the period. Finally, Fernwood Investment Management LLC boosted its holdings in shares of Pliant Therapeutics by 3.4% in the third quarter. Fernwood Investment Management LLC now owns 513,136 shares of the company's stock valued at $5,752,000 after acquiring an additional 16,850 shares in the last quarter. 97.30% of the stock is currently owned by institutional investors.

Pliant Therapeutics Stock Down 3.4 %

Shares of PLRX stock traded down $0.39 during mid-day trading on Friday, reaching $11.21. 672,565 shares of the company were exchanged, compared to its average volume of 411,979. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.26 and a current ratio of 10.26. The business's 50 day simple moving average is $13.43 and its 200 day simple moving average is $13.03. The company has a market capitalization of $682.13 million, a P/E ratio of -3.36 and a beta of 1.05. Pliant Therapeutics has a fifty-two week low of $10.22 and a fifty-two week high of $18.92.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.